1344 related articles for article (PubMed ID: 28300280)
21. S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer.
Nawroth R; Stellwagen F; Schulz WA; Stoehr R; Hartmann A; Krause BJ; Gschwend JE; Retz M
PLoS One; 2011; 6(11):e27509. PubMed ID: 22110663
[TBL] [Abstract][Full Text] [Related]
22. mTORC1 and mTORC2 regulate insulin secretion through Akt in INS-1 cells.
Le Bacquer O; Queniat G; Gmyr V; Kerr-Conte J; Lefebvre B; Pattou F
J Endocrinol; 2013 Jan; 216(1):21-9. PubMed ID: 23092880
[TBL] [Abstract][Full Text] [Related]
23. Constitutive phosphorylation of the mTORC2/Akt/4E-BP1 pathway in newly derived canine hemangiosarcoma cell lines.
Murai A; Asa SA; Kodama A; Hirata A; Yanai T; Sakai H
BMC Vet Res; 2012 Jul; 8():128. PubMed ID: 22839755
[TBL] [Abstract][Full Text] [Related]
24. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways.
Liu L; Li F; Cardelli JA; Martin KA; Blenis J; Huang S
Oncogene; 2006 Nov; 25(53):7029-40. PubMed ID: 16715128
[TBL] [Abstract][Full Text] [Related]
25. p53/TAp63 and AKT regulate mammalian target of rapamycin complex 1 (mTORC1) signaling through two independent parallel pathways in the presence of DNA damage.
Cam M; Bid HK; Xiao L; Zambetti GP; Houghton PJ; Cam H
J Biol Chem; 2014 Feb; 289(7):4083-94. PubMed ID: 24366874
[TBL] [Abstract][Full Text] [Related]
26. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909
[TBL] [Abstract][Full Text] [Related]
27. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
28. PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling.
Woo SY; Kim DH; Jun CB; Kim YM; Haar EV; Lee SI; Hegg JW; Bandhakavi S; Griffin TJ; Kim DH
J Biol Chem; 2007 Aug; 282(35):25604-12. PubMed ID: 17599906
[TBL] [Abstract][Full Text] [Related]
29. Mechanistic Target of Rapamycin Complex 1 (mTORC1) and mTORC2 as Key Signaling Intermediates in Mesenchymal Cell Activation.
Walker NM; Belloli EA; Stuckey L; Chan KM; Lin J; Lynch W; Chang A; Mazzoni SM; Fingar DC; Lama VN
J Biol Chem; 2016 Mar; 291(12):6262-71. PubMed ID: 26755732
[TBL] [Abstract][Full Text] [Related]
30. The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206.
Wang H; Huang F; Wang J; Wang P; Lv W; Hong L; Li S; Zhou J
Cell Cycle; 2015; 14(2):232-42. PubMed ID: 25607647
[TBL] [Abstract][Full Text] [Related]
31. Reciprocal regulation of mTOR complexes in pancreatic islets from humans with type 2 diabetes.
Yuan T; Rafizadeh S; Gorrepati KD; Lupse B; Oberholzer J; Maedler K; Ardestani A
Diabetologia; 2017 Apr; 60(4):668-678. PubMed ID: 28004151
[TBL] [Abstract][Full Text] [Related]
32. High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1.
Yellen P; Saqcena M; Salloum D; Feng J; Preda A; Xu L; Rodrik-Outmezguine V; Foster DA
Cell Cycle; 2011 Nov; 10(22):3948-56. PubMed ID: 22071574
[TBL] [Abstract][Full Text] [Related]
33. CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo.
Dormond O; Contreras AG; Meijer E; Datta D; Flynn E; Pal S; Briscoe DM
J Immunol; 2008 Dec; 181(11):8088-95. PubMed ID: 19018001
[TBL] [Abstract][Full Text] [Related]
34. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
[TBL] [Abstract][Full Text] [Related]
35. Determinants of rapamycin sensitivity in breast cancer cells.
Noh WC; Mondesire WH; Peng J; Jian W; Zhang H; Dong J; Mills GB; Hung MC; Meric-Bernstam F
Clin Cancer Res; 2004 Feb; 10(3):1013-23. PubMed ID: 14871980
[TBL] [Abstract][Full Text] [Related]
36. S6K1 alternative splicing modulates its oncogenic activity and regulates mTORC1.
Ben-Hur V; Denichenko P; Siegfried Z; Maimon A; Krainer A; Davidson B; Karni R
Cell Rep; 2013 Jan; 3(1):103-15. PubMed ID: 23273915
[TBL] [Abstract][Full Text] [Related]
37. A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models.
Zhang H; Berel D; Wang Y; Li P; Bhowmick NA; Figlin RA; Kim HL
PLoS One; 2013; 8(1):e54918. PubMed ID: 23349989
[TBL] [Abstract][Full Text] [Related]
38. Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2.
Luo Y; Liu L; Wu Y; Singh K; Su B; Zhang N; Liu X; Shen Y; Huang S
Oncotarget; 2015 Feb; 6(6):4286-98. PubMed ID: 25738366
[TBL] [Abstract][Full Text] [Related]
39. ASCT2 silencing regulates mammalian target-of-rapamycin growth and survival signaling in human hepatoma cells.
Fuchs BC; Finger RE; Onan MC; Bode BP
Am J Physiol Cell Physiol; 2007 Jul; 293(1):C55-63. PubMed ID: 17329400
[TBL] [Abstract][Full Text] [Related]
40. Dual inhibition by S6K1 and Elf4E is essential for controlling cellular growth and invasion in bladder cancer.
Kyou Kwon J; Kim SJ; Hoon Kim J; Mee Lee K; Ho Chang I
Urol Oncol; 2014 Jan; 32(1):51.e27-35. PubMed ID: 24239466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]